產品名稱：VEGF-R2 Human ELISA Kit
- 產品編號
- BEK1233
- 產品規格
- 96T
- 價格
- 2800.00
- 來源
- -
- 交叉反應
- Human
- 免 疫 原
- -
- 產品簡介
- This kit was based on standard sandwich enzyme-linked immune-sorbent assay technology. The purified anti-VEGFR2 antibody was pre-coated onto 96-well plates. And the HRP conjugated anti-VEGFR2 antibody was used as detection antibodies. The standards, test samples and HRP conjugated detection antibody were added to the wells subsequently, mixed and incubated, then, unbound conjugates were washed away with wash buffer. TMB substrates (A & B) were used to visualize HRP enzymatic reaction. TMB was catalyzed by HRP to produce a blue color product that changed into yellow after adding acidic stop solution. The density of yellow is proportional to the VEGFR2 amount of sample captured in plate. Read the O.D. absorbance at 450nm in a microplate reader, and then the concentration of VEGFR2 can be calculated.
Kit components
1. One 96-well plate pre-coated with anti-human VEGFR2 antibody
2. Standard: 0.5ml (900pg /mL)
3. Standard diluent buffer: 1.5 ml
4. Wash buffer (30×): 20 ml. Dilution: 1:30
5. Sample diluent buffer: 6 ml
6. HRP conjugated anti-human VEGFR2 antibody (RTU): 6ml
7. Stop solution: 6 ml
8. TMB substrate A: 6ml
9. TMB substrate B: 6ml
10. Plate sealer: 2
11. Hermetic bag: 1
- 產品別名
- -
- 產品成分
- -
- 檢測范圍
- 30 pg/ml-800 pg/ml
- 檢測樣品
- For quantitative detection of VEGFR2 in Human serum, plasma, urine, cell culture supernatant or tissue samples.
- 產品應用
- ELISA
- 保存條件
- 2-8℃6個月 -20℃一年
- 背景資料
- VEGF receptors are receptors for vascular endothelial growth factor (VEGF). They play an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis.There are three main subtypes of VEGFR, numbered 1, 2 and 3. VEGFR2, also known as Kinase insert domain receptor (KDR) or Flk1 (Fetal Liver Kinase 1), plays an important role as negative regulator of VEGFA- and VEGFC- mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Furthermore, therapeutic inhibition of VEGFR-2 action is now having an impact in the clinic for the treatment of a number of diseases.
- 參考資料
- 1. Holmes K, Roberts OL, Thomas AM, Cross MJ. (Oct 2007). "Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition.". Cell Signal. 19 (10): 2003–2012. 2. Terman B.I., Dougher-Vermazen M., Carrion M.E., Dimitrov D., Armellino D.C., Gospodarowicz D., Boehlen P. "Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor." Biochem. Biophys. Res. Commun. 187:1579-1586(1992) 3. Waltenberger J., Claesson-Welsh L., Siegbahn A., Shibuya M., Heldin C.H. "Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor." J. Biol. Chem. 269:26988-26995(1994)
